Mechanisms of Action of Anticonvulsants and New Mood Stabilizers

Handbook of Medical Psychiatry

Volumn , Issue , 2003, Pages 767-792

  Post, Robert M ^a   Franaszek, Elzbieta Chalecka ^b   Hough, Christopher J ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3042620911     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780203912485-56     Document Type: Chapter

References (169)

1. Post RM, Frye MA, Denicoff KD, Leverich GS, Kimbrell TA, Dunn RT. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology 19:206-219, 1998.
2. Post RM et al. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 38:152-166, 1998.
3. Post RM. Mood disorders: treatment of bipolar disorders. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry, 7th ed. Baltimore: Lippincott Williams & Wilkins, 2000, pp 1385-1430,.
4. Post RM, Weiss SRB, Clark M, Chuang DM, Hough C, Li H. Lithium, carbamazepine, and valproate in affective illness: biochemical and neuro-biological mechanisms. In: Manji H, Bowden CL, Belmaker RH, eds. Bipolar Medications: Mechanisms of Action. Washington: American Psychiatric Press, 2000, pp 219-248.
5. Fochtmann LJ. Animal studies of electroconvulsive therapy: foundations for future research. Psychopharmacol Bull 30:321-444, 1994.
6. Fink M. Convulsive therapy: a review of the first 55 years. J Affect Disord 63:1-15, 2001.
7. Sackeim HA. The anticonvulsant hypothesis of the mechanisms of action of ECT. Current status. J ECT 15:5-26, 1999.
8. Post RM, Chuang D-M. Mechanism of action of lithium: comparison and contrast with carbamaze-pine. In: Birch NJ, ed. Lithium and the Cell: Pharmacology and Biochemistry. London: Academic Press, 1991, pp 199-241.
9. Post RM. Time course of clinical effects of carbama-zepine: implications for mechanisms of action. J Clin Psychiatry 49(suppl):35-48, 1988.
10. Post RM, Weiss SRB, Chuang D-M, Ketter TA. Mechanisms of action of carbamazepine in seizure and affective disorders. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in Mood Disorders. New York: Marcel Dekker. 1994, pp 43-92.
11. Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 44:324-335, 1998.
12. Thome J et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 20:4030-4036, 2000.
13. Fujimaki K, Morinobu S, Duman RS. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuro-psychopharmacology 22:42-51, 2000.
14. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neuro-trophic factor (BDNF). Pharmacol Biochem Behav 56:131-137, 1997.
15. McKinney WT. Animal models of depression: an overview. Psychiatr Dev 2:77-96, 1984.
16. Loscher W. Animal models of intractable epilepsy. Prog Neurobiol 53:239-258, 1997.
17. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med 49:341-361, 1998.
18. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 152:1130-1138, 1995.
19. Post RM, Denicoff KD, Leverich GS, Frye MA. Drug-induced switching in bipolar disorder. Epidemiology and therapeutic implications. CNS Drugs 8:352-365, 1997.
20. Ahlfors UG et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand 64:226-237, 1981.
21. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 13:156-167, 1980.
22. Weiss SR, Post RM. Caveats in the use of the kindling model of affective disorders. Toxicol Ind Health 10:421-447, 1994.
23. Post RM, Ketter TA, Speer AM, Leverich GS, Weiss SR. Predictive validity of the sensitization and kindling hypotheses. In: Soares JC, Gershon S, eds. Bipolar Disorders: Basic Mechanisms and Therapeutic Implications. New York: Marcel Dekker, 2000, pp 387-432.
24. Post RM, Weiss SRB. Kindling and stress sensitization. In: Joffe RT, Young LT, eds. Bipolar Disorder: Biological Models and Their Clinical Application. New York: Marcel Dekker, 1997, pp 93-126.
25. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53:S53-S67, 1999.
26. Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 60:759-762, 1999.
27. Frye MA et al. A placebo-controlled study of lamo-trigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20:607614, 2000.
28. Post RM, Denicoff KD, Frye MA, Leverich GS. Reevaluating carbamazepine prophylaxis in bipolar disorder. Br J Psychiatry 170:202-204, 1997.
29. Emrich HM, Dose M, Von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 8:243-250, 1985.
30. Emrich HM, Altmann H, Dose M, Von Zerssen D. Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacol Biochem Behav 19:369-372, 1983.
31. Post RM et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl) 128:115-129, 1996.
32. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 36(suppl 2):S2-S- 12,1995.
33. Ketter TA et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 15:387-398, 1995.
34. Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol 25:228-234, 1984.
35. Kuo CC. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol Pharmacol 54:712-721, 1998.
36. Albright P, Burnham W. Effects of phenytoin, car-bamazepine, and clonazepam on cortex- and amygdala-evoked potentials. Exp Neurol 81:308-319, 1983.
37. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 50:691-713, 1995.
38. Hough CJ, Irwin RP, Gao X-M, Rogawski MA, Chuang D-M. Carbamazepine inhibition of N-Methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. J Pharmacol Exp Ther 276:143149, 1996.
39. Grunze H, Von Wegerer J, Greene RW, Walden J. Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 38:131-138, 1998.
40. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 7:30373040, 1996.
41. Stefani A, Spadoni F, Siniscalchi A, Bernardi G. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol 307:113-116, 1996.
42. Marangos PJ, Daval JL, Weiss SRB, Post RM. Carbamazepine and brain adenosine receptors. In: Wasterlain CG, Vert P, eds. Neonatal Seizures. New York: Raven Press, 1990, pp 203-209.
43. Post RM, Weiss SRB, Clark M, Nakajima T, Ketter TA. Seizures as an evolving process: Implications for neuropsychiatric illness. In: Theodore WH, Devinsky O, eds. Epilepsy and Behavior. New York: Alan R. Liss, 1991, pp 361-387.
44. Weiss SRB, Post RM, Marangos PJ, Patel J. Peripheral-type benzodiazepines: behavioral effects and interactions with the anticonvulant effects of carbamazepine. In: Wada JA, ed. Kindling III. New York: Raven Press, 1986, pp 375-389.
45. Krueger KE. Molecular and functional properties of mitochondrial benzodiazepine receptors. Biochim Biophys Acta 1241:453-470, 1995.
46. Papadopoulos V et al. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids 62:21-28, 1997.
47. Syapin PJ, Skolnick P. Characterization of benzodiazepine binding sites in cultured cells of neural origin. J Neurochem 32:1047-1051, 1979.
48. Purdy RE, Julien RM, Fairhurst AS. Effect of car-bamazepine on the in vitro uptake and release of norepinephrine in adrenergic nerves of rabbit aorta and in whole brain synaptosomes. Epilepsia 18:251257, 1977.
49. Post RM et al. Effects of carbamazepine on noradrenergic mechanisms in affectively ill patients. Psychopharmacology (Berl) 87:59-63, 1985.
50. Maitre L, Baltzer V, Mondadori C. Psychopharmacological and behavioural effects of anti-epileptic drugs in animals. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam: Excerpta Medica, 1984, pp 3-13.
51. Chen G, Hough C, Manji H, Chuang DM, Mefford IN, Potter WZ. Upregulation of beta-adrenergic receptors and beta2 mRNA by carbamazepine in vitro. Soc Neuroscie Abstr 1991, p 17.
52. Rubinow DR, Post RM, Gold PW, Uhde TW. Effect of carbamazepine on mean urinary free cortisol excretion in patients with major affective illness. Psychopharmacology (Berl) 88:115-118, 1986.
53. Kling MA et al. Effects of local anesthetics on experiential, physiologic and endocrine measures in healthy humans and on rat hypothalamic corticotropin-releasing hormone release in vitro: clinical and psychobiologic implications. J Pharmacol Exp Ther 268:1548-1564, 1994.
54. Calogero AE, Gallucci WT, Kling MA, Chrousos GP, Gold PW. Cocaine stimulates rat hypothalamic corticotropin-releasing hormone secretion in vitro. Brain Res 505:7-11, 1989.
55. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 143:29-34, 1986.
56. Post RM, Frye MA, Denicoff KD, Kimbrell TA, Cora-Locatelli G, Leverich GS. Anticonvulsants in the long-term prophylaxis of depression. In: Honig A, Van Praag HM, eds. Depression: Neurobiological, Psychopathological and Therapeutic Advances. Sussex, England: John Wiley & Sons, 1997, pp 483-498.
57. Rubinow DR, Post RM, Gold PW, Ballenger JC, Reichlin S. Effects of carbamazepine on cerebrospinal fluid somatostatin. Psychopharmacology (Berl) 85:210-213, 1985.
58. Pazzaglia PJ, George MS, Post RM, Rubinow DR, Davis CL. Nimodipine increases CSF somatostatin in affectively ill patients. Neuropsychopharmacology 13:75-83, 1995.
59. Post RM et al. Carbamazepine and nimodipine in refractory affective illness: Efficacy and mechanisms. In: Halbreich U, Montgomery S, eds. Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders. Washington, DC: American Psychiatric Press, 2000 pp 77-110.
60. Ketter TA et al. Baseline cerebral hypermetabolism associated with carbamazepine response, and hypo-metabolism with nimodipine response in mood disorders. Biol Psychiatry 46:1364-1374, 1999.
61. Frye MA, Kimbrell TA, Willis MW, Ketter TA, George MS, Pazzaglia PJ, Dunn RT, Luckenbaugh D, Huggins T, Little JT, Vanderham L, Danielson A, Benson B, Davis C, Rubinow DR, Post RM. Low CSF somatostatin and cerebral hypometabolism in depression. Biol Psychiatry 41:32S-33S, 1997.
62. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95:13290-13295, 1998.
63. Drevets WC, Ongur D, Price JL. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. Mol Psychiatry 3:220-221, 1998.
64. Drevets WC et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386:824827, 1997.
65. Hong JS, Tilson HA, Yoshikawa K. Effects of lithium and haloperidol administration on the rat brain levels of substance P. J Pharmacol Exp Ther 224:590-593, 1983.
66. Le Douarin C, Oblin A, Fage D, Scatton B. Influence of lithium on biochemical manifestations of striatal dopamine target cell supersensitivity induced by prolonged haloperidol treatment. Eur J Pharmacol 93:55-62, 1983.
67. Mitsushio H, Takashima M, Mataga N, Toru M. Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. J Pharmacol Exp Ther 245:982-989, 1988.
68. Jones RS, Olpe HR. An increase in sensitivity of rat cingulate cortical neurones to substance P occurs following withdrawal of chronic administration of antidepressant drugs. Br J Pharmacol 81:659-664, 1984.
69. Kramer MS et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645, 1998.
70. Nutt D. Substance-P antagonists: a new treatment for depression? Lancet 352:1644-1646, 1998.
71. Gold PW et al. Vasopressin in affective illness: direct measurement, clinical trials, and response to hypertonic saline. In: Post RM, Ballenger JC, eds. Neurobiology of Mood Disorders. Baltimore: Williams & Wilkins, 1984, pp 323-339.
72. Sudha S, Lakshmana MK, Pradhan N. Changes in learning and memory, acetylcholinesterase activity and monoamines in brain after chronic carbamaze-pine administration in rats. Epilepsia 36:416-422, 1995.
73. Joffe RT, Post RM, Uhde TW. Effects of carbama-zepine on serum electrolytes in affectively ill patients. Psychol Med 16:331-335, 1986.
74. Uhde TW, Post RM. Effects of carbamazepine on serum electrolytes: clinical and theoretical implications. J Clin Psychopharmacol 3:103-106, 1983.
75. Yassa R, Iskandar H, Nastase C, Camille Y. Carbamazepine and hyponatremia in patients with affective disorder. Am J Psychiatry 145:339-342, 1988.
76. Brewerton TD, Jackson CW. Prophylaxis of carba-mazepine-induced hyponatremia by demeclocycline in six patients. J Clin Psychiatry 55:249-251, 1994.
77. Ringel RA, Brick JF. Perspective on carbamazepine-induced water intoxication: reversal by demeclocy-cline. Neurol 36:1506-1507, 1986.
78. Vieweg WV, Yank GR, Rowe WT, Hovermale LS, Clayton AH. Increase in white blood cell count and serum sodium level following the addition of lithium to carbamazepine treatment among three chronically psychotic male patients with disturbed affective states. Psychiatr Q 58:213-217, 1986.
79. Motohashi N. GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Prog Neuropsychopharmacol Biol Psychiatry 16:571579, 1992.
80. Bernasconi R. The GABA hypothesis of affective illness: influence of clinically effective antimanic drugs on GABA turnover. In: Emrich HM, Aldenhoff JB, Lux HD, eds. Basic Mechanisms in the Action of Lithium: Proceedings of a Symposium Held at Schloss Ringberg, Bavaria, F.R.G., October 4-6, 1981. Amsterdam: Excerpta Medica, 1982, pp 183-192.
81. McLean MH, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 237:1001-1010, 1986.
82. Slater GE, Johnston D. Sodium valproate increases potassium conductance in aplysia neurones. Epilepsia 19:379-384, 1978.
83. Walden J, Altrup U, Reith H, Speckmann E-J. Effects of valproate on early and late potassium currents of single neurons. Eur Neuropsychopharmacol 3:137-141, 1993.
84. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 63:2361-2364, 1994.
85. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry 60(suppl 2):27-39, 1999.
86. Hong M, Chen DC, Klein PS, Lee VM. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272:2532625332, 1997.
87. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72:1327-1330, 1999.
88. Ozaki N, Chuang DM. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 69:2336-2344, 1997.
89. Chen G, Yuan P, Hawver DB, Potter WZ, Manji HK. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuro-psychopharmacology 16:238-245, 1997.
90. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96:8745-8750, 1999.
91. Chen G et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neu-roprotective protein bcl-2 in the CNS. J Neurochem 72:879-882, 1999.
92. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 274:6039-6042, 1999.
93. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 9:2081-2084, 1998.
94. Manji HK, Moore GJ, Chen G. Clinical and precli-nical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 48:740-754, 2000.
95. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 13:2905-2927, 1999.
96. Datta SR et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241, 1997.
97. Cardone MH et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282:13181321, 1998.
98. Brunet A et al. Akt promotes cell survival by phos-phorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868, 1999.
99. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273:32377-32379, 1998.
100. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605, 1999.
101. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 9:601-604, 1999.
102. Blair LA, Bence-Hanulec KK, Mehta S, Franke T, Kaplan D, Marshall J. Akt-dependent potentiation of L channels by insulin-like growth factor-1 is required for neuronal survival. J Neurosci 19:19401951, 1999.
103. Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/ protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19:5800-5810, 1999.
104. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789, 1995.
105. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 5:578-593, 2000.
106. Wei H, Qin Z, Wei W, Wang Y, Qian Y, Chuang DM. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington’s disease. Neuroscience 106:603-612, 2001.
107. Nonaka S, Katsube N, Chuang DM. Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbama-zepine. J Pharmacol Exp Ther 286:539-547, 1998.
108. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 75:1729-1734, 2000.
109. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20:9104-9110, 2000.
110. Gould E, Tanapat P. Stress and hippocampal neurogenesis. Biol Psychiatry 46:1472-1479, 1999.
111. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Menji HK. Lithium-induced increase in human brain grey matter. Lancet 356:1241-1242, 2000.
112. Moore GJ et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects? Biol Psychiatry 48:1-8, 2000.
113. Lubrich B, Van Calker D. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology 21:519-529, 1999.
114. Bowden CL et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 45:953-958, 1999.
115. Calabrese JR et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 61:841-850, 2000.
116. Guberman AH et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 40:985-991, 1999.
117. Zona C, Avoli M. Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 38:522-525, 1997.
118. Waldmeier PC, Baumann PA, Wicki P, Feldtrauer J-J, Stierlin C, Schmutz M. Similar potency of carba-mazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 45:1907-1913, 1995.
119. Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 35:241-256, 1997.
120. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28:167-179, 1997.
121. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41(suppl 1):S17-S20, 2000.
122. Muller D, Joly M, Lynch G. Contributions of quisqualate and NMDA receptors to the induction and expression of LTP. Science 242:1694-1697, 1988.
123. Aldenkamp AP et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as addon therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 41:1167-1178, 2000.
124. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69:636-641, 2000.
125. Berlant JL. Topiramate in post-traumatic stress disorder: preliminary clinical observations. J Clin Psychiatry 62 (Suppl 17); 60-63, 2001.
126. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 37(suppl 2):S18-S22, 1996.
127. Lhatoo SD, Wong IC, Polizzi G, Sander JW. Longterm retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41:15921596, 2000.
128. Dalby NO, Nielsen EB. Comparison of the preclini-cal anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res 28:63-72, 1997.
129. Taylor CP et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29:233-249, 1998.
130. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2:249-255, 2000.
131. Gerner RH et al. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry 141:15331540, 1984.
132. Post RM et al. Cerebrospinal fluid GABA in normals and patients with affective disorders. Brain Res Bull 5:755-759, 1980.
133. Pande AC et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19:341-348, 1999.
134. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders [letter]. Am J Psychiatry 155:992-993, 1998.
135. Chouinard G, Beauclair L, Belanger MC. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders [letter]. Can J Psychiatry 43:305, 1998.
136. Suppes T, Leverich GS, Keck PE Jr, Nolen W, Denicoff KD, Altshuler LL, McElroy SL, Rush AJ, Kupka R, Bickel M, Post RM. The Stanley Foundation Bipolar Treatment Outcome Network: II. Demographics and illness characteristics of the first 261 patients. J Affect Disord, 67:45-59, 2001.
137. McElroy SL et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 158:420-426, 2001.
138. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 59:480-481, 1998.
139. Merren MD. Gabapentin for treatment of pain and tremor: a large case series. South Med J 91:739-744, 1998.
140. Gironell A, Kulisevsky J, Barbanoj M, Lopez-Villegas D, Hernandez G, Pascual-Sedano B. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 56:475-480, 1999.
141. Adler CH. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol 20:148-151, 1997.
142. Olson WL, Gruenthal M, Mueller ME, Olson WH. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am J Med 102:6066, 1997.
143. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 51:253-260, 2002
144. Schachter SC. The next wave of anticonvulsants— focus on levetiracetam, oxcarbazepine and zonisa-mide. CNS Drugs 14:229-249, 2000.
145. Noyer M, Gillard M, Matagne A, Henichart JP, Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286:137-146, 1995.
146. Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353:191-206, 1998.
147. Georg MD, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 42:281-285, 2000.
148. Margineanu DG, Wulfert E. ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo. Eur J Pharmacol 286:321-325, 1995.
149. Loscher W, Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232:147-158, 1993.
150. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 284:474-479, 1998.
151. Kawata Y et al. Effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus. Epilepsy Res 35:173-182, 1999.
152. Okada M et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 34:187-197, 1999.
153. Fromm GH, Shibuya T, Terrence CF. Effect of zonisamide (CI-912) on a synaptic system model. Epilepsia 28:673-679, 1987. :
154. Okada M et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 22:193-205, 1995.
155. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 5:115-119, 1996.
156. Kanba S et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 18:707-715, 1994.
157. Cohen BM, Baldessarini RJ. Tolerance to therapeutic effects of antidepressants. Am J Psychiatry 142:489-490, 1985.
158. Mann JJ. Loss of antidepressant effect with longterm monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition. J Clin Psychopharmacol 3:363-366, 1983.
159. Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 56:52-55, 1995.
160. Weiss SR, Clark M, Rosen JB, Smith MA, Post RM. Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms. Brain Res Brain Res Rev 20:305-325, 1995.
161. Rosen JB, Weiss SR, Post RM. Contingent tolerance to carbamazepine: alterations in TRH mRNA and TRH receptor binding in limbic structures. Brain Res 651:252-260, 1994.
162. Clark M, Massenburg GS, Weiss SR, Post RM. Analysis of the hippocampal GABAA receptor system in kindled rats by autoradiographic and in situ hybridization techniques: contingent tolerance to carbamazepine. Brain Res Mol Brain Res 26:309319, 1994.
163. Wan RQ, Noguera EC, Weiss SR. Anticonvulsant effects of intra-hippocampal injection of TRH in amygdala kindled rats. Neuroreport 9:677-682, 1998.
164. Pazzaglia PJ, Post RM. Contingent tolerance and reresponse to carbamazepine: a case study in a patient with trigeminal neuralgia and bipolar disorder. J Neuropsychiatry Clin Neurosci 4:76-81, 1992.
165. Krupp E, Heynen T, Li XL, Post RM, Weiss SR. Tolerance to the anticonvulsant effects of lamotri-gine on amygdala kindled seizures: cross-tolerance to carbamazepine but not valproate or diazepam. Exp Neurol 162:278-289, 2000.
166. Weiss SR, Post RM, Sohn E, Berger A, Lewis R. Cross-tolerance between carbamazepine and valproate on amygdala-kindled seizures. Epilepsy Res 16:37-44, 1993.
167. Postma T, Krupp E, Li XL, Post RM, Weiss SR. Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy. Epilepsia 41:1514-1521, 2000.
168. Loscher W, Reissmuller E, Ebert U. Anticonvulsant efficacy of gabapentin and levetiracetam in pheny-toin-resistant kindled rats. Epilepsy Res 40:63-77, 2000.
169. Ebert U, Reissmuller E, Loscher W. The new antiepileptic drugs lamotrigine and felbamate are effective in phenytoin-resistant kindled rats. Neuropharmacology 39:1893-1903, 2000.